Anaptysbio (ANAB) Capital Expenditures Growth (1y) (2017 - 2026)
Anaptysbio (ANAB) Capital Expenditures Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | - |
| 10 | Anaptysbio | 1.56 Bn | 1.27 Bn | - | 54.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.55% |
| Dec 31, 2025 | 2,800.00% |
| Sep 30, 2025 | -32.14% |
| Jun 30, 2025 | 90.91% |
| Mar 31, 2025 | -59.26% |
| Dec 31, 2024 | -98.93% |
| Sep 30, 2024 | -134.57% |
| Jun 30, 2024 | -82.63% |
| Mar 31, 2024 | -84.57% |
| Dec 31, 2023 | 122.22% |
| Sep 30, 2023 | 478.57% |
| Jun 30, 2023 | 445.45% |
| Mar 31, 2023 | 218.18% |
| Dec 31, 2022 | 530.00% |
| Sep 30, 2022 | 102.40% |
| Jun 30, 2022 | -106.37% |
| Mar 31, 2022 | -82.65% |
| Dec 31, 2021 | -93.57% |
| Sep 30, 2021 | -1,428.41% |
| Jun 30, 2021 | 939.76% |